{"DataElement":{"publicId":"6014207","version":"1","preferredName":"Intervention or Procedure BCS SLNB One or More Positive Axillary Nodes Clinical Trial Eligibility Criteria Ind","preferredDefinition":"A response that can have a value of yes, no, or not applicable for questions addressing the presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected after treatment or action taken to prevent or treat disease by breast conservation surgery and the surgical removal and examination of the sentinel node, as outlined in the study protocol to allow a person to participate in the clinical trial.","longName":"BCS_SLNB_ONE_MORE_POS_AXN_IND","context":"CCTG","contextVersion":"1","DataElementConcept":{"publicId":"6014206","version":"1","preferredName":"Intervention or Procedure Breast Conservation Treatment Sentinel Lymph Node Biopsy One or More Positive Axillary Nodes Clinical Trial Eligibility Criteria","preferredDefinition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects._Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990)_Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer._Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"2233215v1.0:6014204v1.0","context":"CCTG","contextVersion":"1","ObjectClass":{"publicId":"2233215","version":"1","preferredName":"Procedure","preferredDefinition":"A particular course of action intended to achieve a result.","longName":"C25218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention or Procedure","conceptCode":"C25218","definition":"An activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. This is a general term that encompasses the medical, social, behavioral, and environmental acts that can have preventive, therapeutic, or palliative effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9313AE8-B7EE-4260-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"ONEDATA","dateModified":"2005-06-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6014204","version":"1","preferredName":"Breast Conservation Treatment Sentinel Lymph Node Biopsy One or More Positive Axillary Nodes Clinical Trial Eligibility Criteria","preferredDefinition":"Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990):Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.:Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C15280:C15667:C8032:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Conservation Treatment","conceptCode":"C15280","definition":"Breast conservation treatment is defined as excision of the primary tumor and adjacent breast tissue, followed by radiation therapy.  This procedure is also referred to as lumpectomy, segmental mastectomy, or partial mastectomy. (from Consensus Statements: Treatment of Early-stage Breast Cancer, 1990)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Sentinel Lymph Node Biopsy","conceptCode":"C15667","definition":"Surgical removal and examination of the sentinel node, the lymph node which is first in receiving the lymphatic drainage of a specified anatomic location and is most likely to be affected by the lymphatic spread of cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"One or More Positive Axillary Nodes","conceptCode":"C8032","definition":"Presence of one or more lymph nodes in the area of the armpit in which cancerous cells have been detected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D00872F-CB58-2706-E053-F662850A7E70","latestVersionIndicator":"Yes","beginDate":"2017-11-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-02","modifiedBy":"ONEDATA","dateModified":"2017-11-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D00872F-CB69-2706-E053-F662850A7E70","latestVersionIndicator":"Yes","beginDate":"2017-11-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-02","modifiedBy":"TAYLORT","dateModified":"2018-11-21","changeDescription":"11-21-18 TT released/CWinch. 11/2/17 tt MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3170966","version":"1","preferredName":"Eligibility Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"3170966v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7858-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7862-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"},{"value":"NA","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"3170967","version":"1","preferredName":"Not Applicable","longName":"3170967","preferredDefinition":"Determination that a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CE1289-786C-BF60-E040-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"97CE1289-7884-BF60-E040-BB89AD437833","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"ONEDATA","dateModified":"2010-12-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2694966","version":"1","preferredName":"Ind-3b","preferredDefinition":"A response or indicator that can have a value of yes, no, or not applicable.","longName":"C49797","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes, No, or Not Applicable Response","conceptCode":"C49797","definition":"A response or indicator that can have a value of yes, no, or not applicable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"3EBCA780-282F-4411-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-11-12","endDate":"2016-04-27","createdBy":"CURTIST","dateCreated":"2007-11-12","modifiedBy":"TAYLORT","dateModified":"2020-10-02","changeDescription":"10.2.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Retired DBW 04-27-2016 per Tina Taylor approved by Dianne Reves","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CE1289-7843-BF60-E040-BB89AD437833","latestVersionIndicator":"Yes","beginDate":"2010-12-19","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-12-19","modifiedBy":"REEVESD","dateModified":"2012-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"BCS_SLNB_ONE_MORE_POS_AXN_IND","type":"USED_BY","context":"CCTG"}],"ReferenceDocuments":[{"name":"If patient was treated by BCS","type":"Preferred Question Text","description":"If patient was treated by BCS and sentinel lymph node biopsy (SLNB) alone, patient has only 1-2 positive axillary nodes (macrometastases, greater than 2 mm).","url":null,"context":"CCTG"},{"name":"ALT_1","type":"Alternate Question Text","description":"If patient had nodal macrometastases (>2 mm) and was treated by sentinel lymph node biopsy (SLNB) alone, patient has only 1-2 positive axillary nodes (macrometastases, greater than 2 mm).","url":null,"context":"CCTG"}],"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D0111D9-1D62-3928-E053-F662850AE59F","latestVersionIndicator":"Yes","beginDate":"2017-11-02","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-11-02","modifiedBy":"WINCHC","dateModified":"2020-12-11","changeDescription":"11-21-18 TT released/CWinch. 11/2/17 tt  MA39","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}